Email [email protected] Dissertation Defining CDK4 Inhibitor-Induced Senescence After Growth Arrest: A New Transition with Clinical Implications (2018) Mentor Andrew Koff, PhD Start Year 2012 End Year 2018 Education University of Arizona Fellowships Geoffrey Beene Graduate Student Fellowship (2013-2014) Publications Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. (2018) CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. pii: S1535-6108(18)30128-4 [Epub ahead of print] Klein ME, Dickson MA, Antonescu C, Qin LX, Dooley SJ, Barlas A, Manova K, Schwartz GK, Crago AM, Singer S, Koff A, Tap WD. (2018) PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene. [Epub ahead of print] Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A. (2017) ATRX is a regulator of therapy induced senescence in human cells. Nat Commun. 8, 386. PMCID: PMC5577318. Kovatcheva M, Klein ME, Tap WD, Koff A. (2017). Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. Mol Cell Oncol. 5, e1384882. PMCID: PMC5791849 [Available on 2018-11-07] Kovatcheva M, Liu DD, Dickson MA, Klein ME, O’Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, Koff A. (2015) MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget, 6, 8226-43. PMCID: PMC4480747. Tula-Sanchez AA, Havas AP, Alonge PJ, Klein ME, Doctor SR, Pinkston W, Glinsmann-Gibson BJ, Rimsza LM, Smith CL. (2013) A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther., 14, 949-61. PMCID: PMC3926892. View a full listing of Mary E. Klein Dooley’s journal articles.
